Literature DB >> 1929586

Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol.

T Yamamoto1, Y Moriwaki, S Takahashi, M Suda, K Higashino.   

Abstract

The effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol were investigated. Pyrazinamide decreased the mean (SEM) fractional clearance of oxypurinol from 19.2 (2.1) to 8.8 (1.5). Probenecid increased the fractional clearance of oxypurinol from 14.1 (3.5) to 24.8 (4.1). Benzbromarone increased the fractional clearance of oxypurinol from 15.6 (2.3) to 33.8 (2.8). These results suggest that oxypurinol may be secreted by 'an organic acid system' and that oxypurinol is reabsorbed at a putative postsecretory site of the renal tubules.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929586      PMCID: PMC1004507          DOI: 10.1136/ard.50.9.631

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  15 in total

1.  Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.

Authors:  J N Colin; R Farinotti; G Fredj; M Tod; J P Clavel; E Vignon; F Dietlin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Separation of hypoxanthine and xanthine from pyrazinamide and its metabolites in plasma and urine by high-performance liquid chromatography.

Authors:  T Yamamoto; Y Moriwaki; S Takahashi; T Hada; K Higashino
Journal:  J Chromatogr       Date:  1986-10-31

3.  Rapid and simultaneous determination of pyrazinamide and its major metabolites in human plasma by high-performance liquid chromatography.

Authors:  T Yamamoto; Y Moriwaki; S Takahashi; T Hada; K Higashino
Journal:  J Chromatogr       Date:  1987-01-23

4.  Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol?

Authors:  D P Mertz; R Eichhorn
Journal:  Klin Wochenschr       Date:  1984-12-17

5.  The effect of dietary protein on the clearance of allopurinol and oxypurinol.

Authors:  W G Berlinger; G D Park; R Spector
Journal:  N Engl J Med       Date:  1985-09-26       Impact factor: 91.245

6.  Hypouricemia due to renal urate wasting. Two types of tubular transport defect.

Authors:  Y Tofuku; M Kuroda; R Takeda
Journal:  Nephron       Date:  1982       Impact factor: 2.847

7.  Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration.

Authors:  S J Appelbaum; M Mayersohn; R T Dorr; D Perrier
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Renal handling of uric acid in normal subjects by means of the pyrazinamide and probenecid tests.

Authors:  J Garcia Puig; F Mateos Antón; A Muñoz Sanz; G Gaspar; A Lesmes; T Ramos; J Ortiz Vázquez
Journal:  Nephron       Date:  1983       Impact factor: 2.847

9.  [Uric acid-lowering effect of a combination of benzbromarone and allopurinol--studies under standardized dietary conditions].

Authors:  W Löffler; W Gröbner; N Zöllner
Journal:  Arzneimittelforschung       Date:  1983

10.  On the metabolism of allopurinol. Formation of allopurinol-1-riboside in purine nucleoside phosphorylase deficiency.

Authors:  S Reiter; H A Simmonds; D R Webster; A R Watson
Journal:  Biochem Pharmacol       Date:  1983-07-15       Impact factor: 5.858

View more
  7 in total

1.  Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.

Authors:  Mattheus K Reinders; Eric N van Roon; Pieternella M Houtman; Jacobus R B J Brouwers; Tim L Th A Jansen
Journal:  Clin Rheumatol       Date:  2007-02-17       Impact factor: 2.980

Review 2.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.

Authors:  Sophie L Stocker; Kenneth M Williams; Andrew J McLachlan; Garry G Graham; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

5.  Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients.

Authors:  Valderilio Feijó Azevedo; Pedro Grachinski Buiar; Laura Helena Giovanella; Carolina Rossetti Severo; Mauricio Carvalho
Journal:  Int J Rheumatol       Date:  2014-02-12

6.  Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus.

Authors:  Hsin-Wen Chang; Ya-Wen Lin; Ming-Hung Lin; Yu-Ching Lan; Ruey-Yun Wang
Journal:  PLoS One       Date:  2019-01-07       Impact factor: 3.240

7.  Trends in physician diagnosed gout and gout therapies in the US: results from the national ambulatory health care surveys 1993 to 2009.

Authors:  Eswar Krishnan; Linjun Chen
Journal:  Arthritis Res Ther       Date:  2013-11-06       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.